Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis (INCOMIN Trial) II: analysis of MRI responses to treatment and correlation with NAb

Abstract

Background In RRMS, clinical exacerbations are usually associated with different types of active lesions at MRI, including: hyperintense lesions on T1-weighted post-gadolinium sequences; new hyperintense lesions or enlarging old lesions on PD/T2-weighted scans; or new hypointense lesions on T1-weighted pre-Gd sequences.

Objective/methods Primary outcome was the occurrence of patients with at least one active MRI lesion of the different types indicated above during treatment with 250 mg every other day (EOD) interferon beta (IFNβ)-1b or 30 mg once weekly (OW) IFNβ-1a in outpatients with RRMS (INCOMIN Trial).

Results The number of patients with at least one ‘active’ lesion, evaluated over the two-year follow-up, was significantly (P=0.014) lower in the EOD IFNβ-1b arm (13/76, 17%) then in the OW IFNβ-1a arm (25/73, 34%). NAb frequency over two-year follow-up was 22/65 (33.8%) in the EOD IFNβ-1b arm and 4/62 (6.5%) in the OW IFNβ-1a arm, significantly greater in the EOD IFNβ-1b arm.

Conclusions The development of MRI active lesions is strongly reduced by EOD-IFNβ-1b compared with OW-IFNβ-1a, indicating that EOD-IFNβ-1b is more effective than OW-IFNβ-1a in reducing ongoing inflammation and demyelination in MS. Logistic regression showed that NAb status did not affect the risk of MRI activity.

Keywords

burden of disease (BOD)interferon beta-1a interferon beta-1b interferon beta dose relapsing-remitting multiple sclerosis (RRMS)magnetic resonance imaging (MRI)MRI active lesions neutralizing antibodies to interferon beta (NAb)

Get full access to this article

View all access options for this article.

References

The IFN-BETA Multiple Sclerosis Study Group . Interferon beta-1b is effective in relapsing - remitting multiple sclerosis. Clinical results of a multicenter, randomized, double-bind, placebo-controlled trial . Neurology 1993; 43: 655-661 .

The PRISMS Study Group . Randomized, double-blind placebo-controlled study of interferon beta-1a in relapsing - remitting multiple sclerosis: clinical results . Lancet 1998; 352: 1498-1504 .

Jacobs LD , Cookfair DL , Rudick RA , Herndon RM , Richert JR , Salazar AM et al. The Multiple Sclerosis Collaborative Research Group (MSCRG). Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis . Ann Neurol 1996; 39: 285-292 .

Panitch H , Goodin DS , Francis G , Chang P , Coyle PK , O’Connor P et al. EVIDENCE Study Group. Randomized, comparative study of interferon beta-1a treatment regimens in MS: the EVIDENCE Trial . Neurology 2002; 59: 1496-1506 .

Zhao GJ , Koopmans RA , Li DK , Bedell L , Paty DW. Effect of interferon beta-1b in MS: assessment of annual accumulation of PD/T2 activity on MRI. UBC MS/MRI Analysis Group and the MS Study Group . Neurology 2000; 54: 200-206 .

Miller DH , Albert PS , Barkhof F , Francis G , Frank JA , Hodgkinson S et al. Guidelines for the use of magnetic resonance techniques in monitoring the treatment of multiple sclerosis . Ann Neurol 1996; 39: 6-16 .

Molyneux PD , Filippi M , Barkhof F , Gasperini C , Yousry TA , Truyen L et al. Correlations between monthly enhanced MRI lesion rate and changes in T2 lesion volume in multiple sclerosis . Ann Neurol 1998; 43: 332-339 .

Antonelli G , Bagnato F , Pozzilli C , Simeoni E , Bastianelli S , Currenti M et al. Development of neutralizing antibodies in patients with relapsing remitting multiple sclerosis treated with IFN beta-1a . J Interferon Cytokine Res 1998; 18: 45-50 .

Durelli L , Verdun E , Barbero P , Bergui M , Versino E , Ghezzi A , and the Independent Comparison of Interferon (INCOMIN) Trial Study Group . Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN) . Lancet 2002; 359: 1453-1460 .

10.

Rosenthal R. Parametric measures of effect size. In Copper H , Hedges LV eds. The handbook of research synthesis. Russell Sage Foundation , 1991: 231-244.